VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
MNPR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksMNPRInstitutional Holders

MNPR logoMonopar Therapeutics Inc. (MNPR) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership decreased this quarter (-0.39 pp), while top 10 holders maintain a highly concentrated 65.8% of value.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
92.9%$575M total value · ▼ 0.39 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
49 / 100Neutral
Institutions & Flow95 holders+13 net flow (+27 / -14)

AI Insights & Key Takeaways

  • Positive Institutional Flow (+13)
  • Millennium Management Llc maintains a significant position
  • Top 10 holders control 65.8% of institutional value
  • No Insider Signal

Top Institutional Holders of MNPR

Ranked by reported Q2 2026 13F market value

Top 10 Holders
65.8%
Top 25 Holders
91.4%

Share of total reported institutional value in MNPR held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1Jupiter Topco LLC1.3M$121.7M—19.587%0.05%
2RA CAPITAL MANAGEMENT, L.P.667K$61.8M0.0%9.960%0.54%
3BlackRock, Inc.349K$32.3M+10.2%5.207%0.00%

Quarterly Institutional Activity

Filings activity in MNPR during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers27Added To58Trimmed8Exited14
  • Sio Capital Management, LLC$9.5M
  • Walleye Capital LLC$3.5M

MNPR Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 202695+16%92.88%0.39 pp$575M+70%
Q1 202682+12%93.27%+10.61 pp$339M5.4%
Q4 202573+33%82.66%+17.46 pp$358M+1.1%
Q3 202555+25%65.20%+13.26 pp$354M+214%
Q2 202544+22%51.94%+4.65 pp$113M+3.5%
Q1 202536+89%

How MNPR Compares to Peers

Institutional ownership and quarterly buying activity across the largest Rare Disease Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
IRLAIRulya Therapeutics Inc.$39M23.9%42-29

MNPR — Frequently Asked Questions

Quick answers to the most common questions about buying MNPR stock.

What percentage of MNPR is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of Monopar Therapeutics Inc. stands at 92.9%, held across 95 reporting institutions.

Who is the largest institutional holder of MNPR?

Jupiter Topco LLC is the largest reported institutional holder of MNPR, with approximately 1,312,129 shares worth $0.12B as of Q2 2026.

Is MNPR a hedge fund favorite?

Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of MNPR, including MILLENNIUM MANAGEMENT LLC.

What is MNPR's Smart Money Score?

Our composite Smart Money Score for MNPR is 49 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought MNPR this quarter?
4
DEERFIELD MANAGEMENT COMPANY, L.P.
324K
$30.0M
0.0%
4.833%
0.31%
5Saturn V Capital Management LP312K$28.9M-9.7%4.657%4.14%
6Siren, L.L.C.270K$25.0M0.0%4.032%0.51%
7ADAR1 Capital Management, LLC218K$20.1M-17.7%3.248%0.92%
8Polar Capital Holdings Plc214K$19.9M-5.3%3.202%0.05%
9VANGUARD CAPITAL MANAGEMENT LLC210K$19.4M-4.0%3.131%0.00%
10ADAGE CAPITAL PARTNERS GP, L.L.C.209K$19.4M-32.3%3.123%0.03%
11TCG Crossover Management, LLC203K$18.8M+53.9%3.035%0.45%
12WELLINGTON MANAGEMENT GROUP LLP158K$14.7M-9.1%2.365%0.00%
13ORBIMED ADVISORS LLC157K$14.6M—2.350%0.27%
14Candriam S.C.A.143K$13.3M—2.140%0.06%
15BALYASNY ASSET MANAGEMENT L.P.135K$12.5M-1.4%2.008%0.02%
16GEODE CAPITAL MANAGEMENT, LLC113K$10.4M+12.7%1.681%0.00%
17Alyeska Investment Group, L.P.100K$9.3M0.0%1.493%0.02%
18STATE STREET CORP93K$8.6M+4.8%1.382%0.00%
19Vivo Capital, LLC91K$8.4M0.0%1.351%0.77%
20DRIEHAUS CAPITAL MANAGEMENT LLC84K$7.8M+153.5%1.255%0.05%
21Bank of New York Mellon Corp77K$7.1M-2.1%1.149%0.00%
22Vestal Point Capital, LP76K$7.0M+15.8%1.130%0.16%
23Longaeva Partners L.P.56K$5.2M—0.834%0.11%
24Neuberger Berman Group LLC55K$5.1M+30.1%0.824%0.00%
25MILLENNIUM MANAGEMENT LLC50K$4.7M-5.0%0.751%0.00%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in MNPR — a direct measure of their conviction.

SILVERARC CAPITAL MANAGEMENT, LLC
$2.4M
  • Jump Financial, LLC$1.2M
  • Squarepoint Ops LLC$1.2M
  • SEI INVESTMENTS CO$415K
  • Informed Momentum Co LLC$341K
  • TD ASSET MANAGEMENT INC$322K
  • MANUFACTURERS LIFE INSURANCE COMPANY, THE$251K
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP$227K
  • Quadrature Capital Ltd$201K
  • Your Advocates Ltd., LLP$183K
  • 47.29%
    +4.96 pp
    $109M
    +91%
    Q4 202419+171%42.33%+41.88 pp$57M+53861%
    Q3 20247—0.45%—$0M—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    27 institutions opened new positions in MNPR during Q2 2026, while 14 fully exited. 58 added to existing positions and 8 trimmed.

    How is institutional ownership of MNPR changing?

    MNPR institutional ownership fell by 0.39 percentage points quarter-over-quarter, with a net change of +13 holders.

    How concentrated is MNPR ownership among the top holders?

    The top 10 institutions account for 65.8% of all reported 13F value in MNPR, and the top 25 account for 91.4%.

    How does MNPR compare to Rare Disease Biotech on institutional ownership?

    Across the largest Rare Disease Biotech peers, institutional ownership levels are: IRLA (23.9%). See the peer comparison table on this page for net buyer activity by company.

    Where does this MNPR institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    MNPRMonopar Therapeutics Inc.
    $70.75$474M
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership